Apolipoprotein E isoforms and apolipoprotein AI protect from amyloid precursor protein carboxy terminal fragment‐associated cytotoxicity
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Inheritance of the apolipoprotein (APO) E gene ɛ4 or ɛ2 allele alters the risk of developing Alzheimer disease (AD), while increased alpha‐tocopherol (AT) intake appears to lower the risk of AD. As APOE is a major apolipoprotein in the CNS and AT in vivo is transported in lipoproteins, we tested the hypothesis that CNS lipoproteins, as modeled by relevant concentrations of high density lipoprotein (HDL), and AT would interact to suppress neurotoxicity in a cell culture model of amyloid beta (Aβ)‐ related toxicity. These cells conditionally express C99‐derived peptides, proposed to be a key step in AD pathogenesis; this expression is closely associated with subsequent cell death. We found that physiologic concentrations of lipoproteins present in the CNS protected from C99‐associated toxicity and provided evidence for two mechanisms of protection. The first was AT‐independent, APOE isoform‐dependent, and most potent for the APOE2 isoform. The second was a synergistic protection afforded by a combination of APOAI, or less so APOE, and AT. These data provide a novel explanation for the apparent AD‐protective effect of inheriting an ɛ2 APOE allele, and suggest that optimizing AT enrichment of CNS lipoproteins or devising APOAI mimetics may augment AT efficacy in treating AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380 · cited 1×
“…supplementation with AT provided modest benefit to patients with established AD, and some, but not all, observational studies that associated dietary supplementation with vitamins E and C or diets high in these antioxidants with reduced risk of developing AD (Sano et al. 1997; Zandi et al. 2004).”
BackgroundProtective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920 · cited 2×
“Genetic linkage studies have consistently associated an increased risk of AD with inheritance of the e4 APOE allele and a decreased risk of AD with the e2 APOE allele (Corder et al. 1993; Corder et al. 1994).”
BackgroundAdvanced glycation end products contribute to amyloidosis in Alzheimer disease
Vitek, M. P., Bhattacharya, K., Glendening, J. M., Stopa, E., Vlassara, H., Bucala, R., Manogue, K., & Cerami, A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4766 · Cited by 806 · cited 1×
“In fact, secretion of several molecules has been demonstrated to be APOE isoformdependent (Vitek et al. 1994) Thus, the partial cytoprotection seen with recombinant APOE2 and the complete cytoprotection seen with APOE2 CM, both of which were isoformspecific, were consistent with both a direct and…”
BackgroundHuman apolipoprotein E. The complete amino acid sequence
Rall, S. C., Weisgraber, K. H., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34702-1 · Cited by 741 · cited 1×
“Humans possess three common alleles of the APOE gene (APOE), e2, e3, and e4, which are expressed as APOE2, APOE3, and APOE4 isoforms, respectively (Rall et al. 1982).”
BackgroundSullivan, P. M., Mezdour, H., Aratani, Y., Knouff, C., Najib, J., Reddick, R. L., Quarfordt, S. H., & Maeda, N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.29.17972 · Cited by 575 · cited 1×
“Homozygous APOE2, APOE3 and APOE4 targeted replacement (TR) mice ‘humanized’ at apoE were developed by Dr Maeda and colleagues (Sullivan et al. 1997; Sullivan et al. 1998).”
BackgroundSelf-citationPhenotypes of apolipoprotein B and apolipoprotein E after liver transplantation.
Linton, M. F., Gish, R., Hubl, S. T., Bütler, E., Esquivel, C., Bry, W. I., Boyles, J. K., Wardell, M. R., & Young, S. G. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115288 · Cited by 367 · cited 1×
“CNS APOE is largely produced in astrocytes, secreted on nascent lipoproteins, and remains distinctly separated from peripheral APOE (Linton et al. 1991; LaDu et al. 1998).”
BackgroundNascent astrocyte particles differ from lipoproteins in CSF
LaDu, M. J., Gilligan, S. M., Lukens, J. R., Cabana, V. G., Reardon, C. A., Van Eldik, L. J., & Holtzman, D. M. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70052070.x · Cited by 285
Apolipoproteins in human cerebrospinal fluid.
Roheim, P. S., Carey, M., Forte, T., & Vega, G. L. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4646 · Cited by 282 · cited 2×
“For comparison, the protein concentration of HDL-like particles in human CSF is approximately 10 lg/mL (Roheim et al. 1979) (p < 0.01 for all points except 0 and 6 lg/mL HDL).”
BackgroundInfluentialSullivan, P. M., Mezdour, H., Quarfordt, S. H., & Maeda, N. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2673 · Cited by 264 · cited 1×
“Homozygous APOE2, APOE3 and APOE4 targeted replacement (TR) mice ‘humanized’ at apoE were developed by Dr Maeda and colleagues (Sullivan et al. 1997; Sullivan et al. 1998).”
BackgroundSelf-citationButterfield, D. A., Koppal, T., Subramaniam, R., & Yatin, S. (1999) · Reviews in the Neurosciences · doi:10.1515/revneuro.1999.10.2.141 · Cited by 97
Cited by
The Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide
Soscia, S. J., Kirby, J. E., Washicosky, K. J., Tucker, S. M., Ingelsson, M., Hyman, B., Burton, M. A., Goldstein, L. E., Duong, S., Tanzi, R. E., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009505 · Cited by 1,060
“different receptors and other molecules [2,3,4], transported by”
Lack of ABCA1 Considerably Decreases Brain ApoE Level and Increases Amyloid Deposition in APP23 Mice
Koldamova, R., Staufenbiel, M., & Lefterov, I. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504513200 · Cited by 350
Lewis, T. L., Cao, D., Lu, H., Mans, R. A., Su, Y. R., Jungbauer, L., Linton, M. F., Fazio, S., LaDu, M. J., & Li, L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.127829 · Cited by 208
The Proteasome and Oxidative Stress in Alzheimer's Disease
Bonet-Costa, V., Pomatto, L. C.-D., & Davies, K. J. A. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6802 · Cited by 99
Li, X., Montine, K. S., Keene, C. D., & Montine, T. J. (2015) · The FASEB Journal · doi:10.1096/fj.14-262683 · Cited by 54
Self-citation
Metadata
- Authors
- Maezawa, I., Jin, L., Woltjer, R. L., Maeda, N., Martin, G. M., Montine, T. J., & Montine, K. S.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2004-12
- Volume
- 91
- Issue
- 6
- Pages
- 1312-1321
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1597103917
- Cited by
- 50
- References
- 10
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.